Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors

医学 立体定向放射治疗 放射科 医学物理学 放射治疗 放射外科 内科学
作者
Tobias Finazzi,Cornelis J.A. Haasbeek,F. Spoelstra,Miguel Palacios,M. Admiraal,A. Bruynzeel,B.J. Slotman,Frank J. Lagerwaard,Suresh Senan
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:107 (2): 270-278 被引量:72
标识
DOI:10.1016/j.ijrobp.2020.02.025
摘要

Purpose

Magnetic resonance (MR)-guided SABR was performed for patients with lung tumors in whom treatment delivery was challenging owing to tumor location, motion, or pulmonary comorbidity. Because stereotactic MR-guided adaptive radiation therapy (SMART) is a novel approach, we studied clinical outcomes in these high-risk lung tumors.

Methods and Materials

Fifty consecutive patients (54 lung tumors) underwent SMART between 2016 and 2018 for either a primary lung cancer (29 patients) or for lung metastases (21 patients). Eligible patients had risk factors that could predispose them to toxicity, including a central tumor location (n = 30), previous thoracic radiation therapy (n = 17), and interstitial lung disease (n = 7). A daily 17-second breath-hold MR scan was acquired in treatment position, and on-table plan adaptation was performed using the anatomy of the day. Gated SABR was delivered during repeated breath-holds under continuous MR guidance.

Results

All but 1 patient completed the planned SMART schedule. With daily plan adaptation, a biologically effective dose ≥100 Gy to 95% of the planning target volume was delivered in 50 tumors (93%). Median follow-up was 21.7 months (95% confidence interval, 19.9-28.1). Local control and overall and disease-free survival rates at 12 months were 95.6%, 88.0%, and 63.6%, respectively. Local failures developed in 4 patients: in 2 after reirradiation for a recurrent lung cancer and in 2 patients with a colorectal metastasis. Overall rates of any grade ≥2 and ≥3 toxicity were 30% and 8%, respectively. Commonest toxicities were grade ≥2 radiation pneumonitis (12%) and chest wall pain (8%). No grade 4 or 5 toxicities were observed.

Conclusions

Use of MR-guided SABR resulted in low rates of high-grade toxicity and encouraging early local control in a cohort of high-risk lung tumors. Additional studies are needed to identify patients who are most likely to benefit from the SMART approach.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
打打应助drinkliu采纳,获得10
刚刚
大菠萝完成签到,获得积分10
刚刚
小城故事和冰雨完成签到,获得积分10
1秒前
liuhang完成签到,获得积分10
1秒前
今天完成签到 ,获得积分10
2秒前
yu完成签到,获得积分10
2秒前
Hello应助yaoyuxuan采纳,获得10
2秒前
nicheng完成签到 ,获得积分10
2秒前
许峰完成签到,获得积分10
3秒前
支持实现完成签到,获得积分10
4秒前
呆萌沛蓝完成签到,获得积分10
4秒前
大个应助暴欣采纳,获得10
5秒前
清酒完成签到,获得积分10
5秒前
纳格兰完成签到,获得积分10
5秒前
科研通AI6.2应助ztq采纳,获得10
5秒前
5秒前
大鱼等雨完成签到,获得积分10
6秒前
7秒前
8秒前
mito完成签到,获得积分10
9秒前
WJ1989完成签到,获得积分10
10秒前
王哈哈完成签到,获得积分10
10秒前
美好灵寒完成签到 ,获得积分0
10秒前
所所应助大菠萝采纳,获得10
10秒前
那小子真帅完成签到,获得积分10
10秒前
尔尔完成签到,获得积分10
10秒前
11秒前
11秒前
fields完成签到,获得积分10
11秒前
11秒前
秋天发布了新的文献求助10
12秒前
月尽天明完成签到,获得积分10
13秒前
13秒前
dun发布了新的文献求助10
14秒前
李健应助小毕可乐采纳,获得10
14秒前
敬敬完成签到,获得积分10
14秒前
pero发布了新的文献求助10
14秒前
光年完成签到,获得积分10
15秒前
JamesPei应助罗擎采纳,获得10
15秒前
SS完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场现状调查及投资机会研判报告 1000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Introducing the Learning Sciences 600
Resiliency Scale for Adolescents--Chinese Version 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7324311
求助须知:如何正确求助?哪些是违规求助? 8939737
关于积分的说明 18953791
捐赠科研通 6981030
什么是DOI,文献DOI怎么找? 3215354
关于科研通互助平台的介绍 2382758
邀请新用户注册赠送积分活动 2194656